Onesource Pharma Reports FY26 Results: Standalone Profit, Group Loss, and Auditor Change

Onesource Specialty Pharma Ltd has released its audited financial results for the fiscal year ending March 31, 2026. The company reported consolidated revenue of ₹1,421.59 crore, alongside a net loss of ₹67.07 crore.

In contrast, the company's standalone operations demonstrated profitability, generating ₹1,420.39 crore in revenue and a net profit of ₹20.00 crore for the same period.

Key Financials and Auditor Appointment

The Board of Directors also approved the appointment of B S R & Co LLP as the new statutory auditors. This appointment is for a term of five consecutive years, succeeding Deloitte Haskins & Sells. The auditors issued an unmodified opinion on the company's FY26 financial statements, confirming the reported figures.

Understanding the Financial Disparity

The significant difference between the consolidated loss and standalone profit suggests that group-level expenses or the performance of subsidiaries are impacting the overall consolidated results. This highlights the need for investors to look closely at both standalone and consolidated figures.

Ongoing Legal Challenge

A major factor for the company remains an ongoing arbitration proceeding with Prestige Biopharma Limited. The case involves a claim of USD 136.32 million (approximately ₹1,286.22 crore). Onesource Specialty Pharma maintains that these claims are without merit.

Investor Focus Areas

Shareholders will be monitoring several key aspects: the company's FY26 financial performance, particularly how standalone strengths translate to consolidated profitability. The new auditors, B S R & Co LLP, will bring a fresh perspective to the financial reporting over their five-year tenure. Additionally, developments in the substantial arbitration claim are crucial.

Key Risk: Arbitration Case

The primary risk for Onesource Specialty Pharma continues to be the arbitration with Prestige Biopharma, which seeks USD 136.32 million. Although the company views the claims as unfounded, an unfavorable outcome could severely affect its financial standing.

Industry Context

Onesource Specialty Pharma operates within the pharmaceutical sector, manufacturing Active Pharmaceutical Ingredients (APIs) and finished dosages. Competitors such as Laurus Labs and Suven Pharmaceuticals operate in similar API and formulations segments. Eris Lifesciences, focusing on branded generics, is another comparable mid-cap entity in the sector. These companies navigate common challenges including margin pressures, regulatory environments, and R&D investment needs.

Looking Ahead

Investors will watch for management's commentary on the drivers of standalone profits and the reasons for the consolidated loss. Progress and any resolution in the Prestige Biopharma arbitration will be critical. The company's ability to achieve consistent consolidated profitability from its operational strengths will also be a key metric to track.